October 2014

New Product - Kalydeco

Kalydeco (ivacaftor) is a selective potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In vitro ivacaftor increases CFTR channel gating to enhance chloride transport. Kalydeco is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D or other gating (class III) mutation in the CFTR gene. It is available as a 150 mg tablet in packs of 56's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au